Syrma SGS Technology just delivered a quarter that makes you sit up and notice. Revenue jumped 73.6% year-on-year to nearly ₹2,000 crore, and profit after tax (PAT) soared 87% to ₹124 crore. Meanwhile, Dixon Technologies reported a 46.7% revenue surge to ₹21,794 crore but watched its net profit crash 48.7% to ₹343.7 crore. Investor Presentation +1
Same quarter. Same sector. Wildly different outcomes. Here's what's actually driving these divergent stories.
Syrma's growth didn't happen by accident. The company has been methodically building its client base across five verticals: automotive, consumer, industrials, IT and railways, and healthcare. In Q1 FY27 alone, Syrma onboarded 18 new clients—five in automotive, three in industrials, two in healthcare, and the rest across telecom and IT. Management estimates these could add more than ₹1,000 crore in revenue at full ramp-up, though volumes start next year and full ramp takes longer. Transcript +1
The order book tells another part of the story. At the end of June 2026, Syrma's order book stood at about ₹6,770 crore, with roughly ₹5,400 crore expected to be executed within 12 months. That's serious visibility. Exports, which now make up 25% of revenue, grew 80% year-on-year to ₹9,012 million. The US and Europe remain key markets, and Syrma has positioned itself with a factory and engineering presence in Stuttgart, Germany. Transcript +3
Dixon's revenue jump to ₹21,794 crore is impressive in absolute terms—it's more than ten times Syrma's revenue. But the quality of that revenue differs significantly. Dixon's business is heavily weighted toward mobile and IT hardware, which management has described as roughly two-thirds of revenue. These are volume-heavy, pass-through businesses where high-value components like chips and memory flow through the books but don't leave much margin behind. Transcript
The growth rates tell a story of market positioning. Syrma's 74% growth comes off a smaller base but reflects broad-based expansion across diversified verticals. Dixon's 47% growth, while substantial, is concentrated in segments where margins are inherently thinner. The mobile PLI 1 incentives ended in March 2026, which management said hurt short-term percentage profitability. Dixon is now participating in mobile PLI 2 and the ECMS scheme, but the benefits will take time to flow through. Transcript
Syrma's revenue mix shifted meaningfully in Q2. Consumer electronics, which was 34% of revenue in Q1, fell to 29% in Q2. Management had previously flagged that consumer is uneven across quarters and expects it to settle at about 30% of annual revenue. The real stars this quarter were automotive (up 91% year-on-year to ₹5,169 crore), industrials (up 86% to ₹4,935 crore), and IT and railways (up 69% to ₹2,727 crore). Investor Presentation +2
IT and railways saw the most dramatic jump, rising 82% quarter-on-quarter and lifting its mix from 9% to 14%. Healthcare held steady at 7% of revenue, with an order book of about ₹500 crore including RFID and MedTech. The MedTech subsidiary, Syrma Johari MedTech, did about ₹210 crore last year and is expected to grow about 50% this year. Investor Presentation +1
Here's where the story gets interesting. Syrma's PAT rose from ₹663 crore to ₹1,242 crore, an 87.2% increase. Dixon's net profit fell from ₹670 crore to ₹343.7 crore. The divergence isn't just about revenue—it's about what's happening below the operating line. Investor Presentation +1
For Syrma, operating expenses grew only 43.4% against 74% revenue growth. Depreciation was almost flat at 3.8% growth, and finance costs rose just 20.8%. That's operating leverage in action—fixed costs getting spread across a much larger revenue base. The effective tax rate also improved slightly to about 24.8% from 25.9%. Investor Presentation +2
Dixon's story is different. Its EBITDA actually rose 6.4% to ₹597 crore, but EBITDA margin contracted to 2.7% from 3.8%. The bigger hit came from other income, which plummeted to ₹69 crore from ₹496 crore in the year-ago quarter. That's a drop of about ₹427 crore. But there's more to it. Dixon's Q2 FY26 results included a one-time PLI-related gain. Management had said adjusted PAT for that quarter was ₹323 crore against the reported ₹670 crore. If that's the like-for-like base, Q2 FY27 profit of ₹343.7 crore would actually be roughly 6% higher. The reported decline is largely a base effect. Transcript +1
Syrma's margins tell a clear story of leverage. Gross margin fell 2.7 percentage points to 21.1%, but operating expenses as a percentage of revenue dropped by about 2.4 percentage points. That offset nearly 90% of the gross margin decline, leaving EBITDA margin down only 0.6 percentage points at 10.2%. Depreciation as a percentage of revenue fell from 1.9% to 1.1%, and PAT margin actually improved 0.5 percentage points to 6.2%. Investor Presentation +2
Management has guided to a full-year EBITDA margin of 10.5–11%, which already factors in margin initiatives and supply-chain pressure. The Q2 result of 10.2% sits just below that range. On pricing, management said component cost increases are passed through to customers, protecting absolute rupee margins but leaving percentage margins slightly lower because there's "no value add on the price increase". Transcript +3
That's ambitious but not impossible. H1 FY27 revenue was about ₹3,578 crore, already close to the entire FY25 revenue of about ₹3,800 crore. If Q3 and Q4 average ₹2,100–2,300 crore, FY27 would land near ₹8,000 crore. Then $1 billion in FY28 would require only about 13–25% growth—well below the 35%+ management has guided for FY27 and FY28. Transcript +1
The order book of ₹6,770 crore, with ₹5,400 crore executable in 12 months, provides strong visibility. The 18 new clients onboarded in Q1, with potential to add ₹1,000 crore at full ramp-up, support FY28 growth. Capacity utilization at 65–70% leaves headroom for incremental revenue without massive new capex. Transcript +4
Syrma is backing its ambition with serious capacity investments. The PCB plant in Andhra Pradesh, with a total program of about ₹800 crore across phases, is on track to be powered on by March 2027. Commercial production is expected by April 2027. At full ramp-up, management expects PCB EBITDA of 15–18% excluding incentives, though initially it may be 10% or lower. This backward integration addresses a critical bottleneck—management has flagged PCB shortages as the biggest worry. Transcript +2
Ex-PCB capex for FY27 is guided at ₹100–150 crore, with capacity additions at Bangalore, a parallel facility, and Pune. A new Bengaluru facility under the Elemaster joint venture and a medical plastics facility in Jodhpur were inaugurated in Q2. The MedTech subsidiary is expected to cross ₹500 crore next year. Transcript +1
Funding this expansion without diluting equity is a key part of the strategy. Management said no additional funds are needed for the PCB project, with funding split between 50–60% debt for phase 1, about 50% government capex subsidy, internal accruals, and a treasury balance of more than ₹800 crore. However, the balance sheet shows debt rising to ₹746 crore by September 2026 from ₹353 crore in March, with net cash falling to ₹258 crore from ₹467 crore. Working capital loans jumped from ₹286 crore to ₹695 crore, reflecting inventory build for new programs. Transcript +4
Syrma and Dixon operate in the same sector but with fundamentally different business models.
Design-led work carries higher margins and more customer stickiness. Investor Presentation +2
Dixon's model is volume-led, with mobile and IT hardware making up roughly two-thirds of revenue. These are assembly-heavy, pass-through businesses where margins are inherently thinner. Refrigerators are described as ODM-led, and LED TV is set to move to an OEM model for mini LED. Dixon is pursuing backward integration into camera modules and displays, with management expecting these to restore operating margins from FY28. Transcript +4
Syrma's path to $1 billion looks credible given the order book, client pipeline, and capacity expansion. The risks are supply-chain constraints, particularly in PCBs and active components, and the need to manage working capital as inventory builds for new programs. Margin guidance of 10.5–11% for the full year is achievable if operating leverage continues and mix remains favorable. Transcript +2
Dixon's near-term challenges are clearer. The base effect from last year's one-time gain will fade, but margin recovery depends on successful execution of backward integration projects and the flow-through of PLI 2 and ECMS incentives. The mobile and IT hardware segments face competitive intensity and pricing pressure. Transcript +1
The EMS sector in India is at an inflection point. Global supply chain diversification is creating opportunities, but competitive intensity is rising as larger groups enter electronics. Syrma and Dixon are taking different paths to the same opportunity—Syrma through diversified, design-led growth, and Dixon through scale and volume. The next few quarters will reveal which approach delivers better returns. Transcript
